title: NQ-Y15 inhibits the calcium mobilization by elevation of cyclic AMP in rat platelets.
abstract: 2-1(4-Cyanophenyl)aminol-3-chloro-1,4-naphthalenedione (NQ-Y15) is a dual action drug which acts as a thromboxane A2 (TXA2) synthase inhibitor and TXA2/PGH2 receptor antagonist. In the present study, we examined the effects of NQ-Y15 on Ca2+ mobilization, which is the common event in various types of platelet activation, in arachidonic acid (AA)-stimulated rat platelets. The elevation of cytosolic Ca2+ concentration ([Ca2+]i) induced by AA was inhibited by NQ-Y15 in a concentration-dependent manner. This inhibition-effect of NQ-Y15 was found to be based on the suppression of the rise in [Ca2+]i by the inhibition of both Ca2+ release from internal stores and Ca2+ influx from the extracellular space. Our successive trial was focused on the role of cyclic AMP (cAMP) in the action of NQ-Y15, because cAMP was reported to be increased by dual action drugs such as picotamide and to inhibit the increase in [Ca2+]i. NQ-Y15 was confirmed to increase cAMP in AA-stimulated rat platelets. These results suggested that NQ-Y15 might inhibit the rise in [Ca2+]i in AA-treated rat platelets by increasing cAMP, which is involved in the inhibition of platelet activation.
authors.affiliation: College of Pharmacy, Seoul National University, Korea.
authors.forename: T S
authors.initials: TS
authors.lastname: Chang
authors.forename: K S
authors.initials: KS
authors.lastname: Lee
authors.forename: G Y
authors.initials: GY
authors.lastname: Lee
authors.forename: S D
authors.initials: SD
authors.lastname: Jeon
authors.forename: D S
authors.initials: DS
authors.lastname: So
authors.forename: L Y
authors.initials: LY
authors.lastname: Khil
authors.forename: M K
authors.initials: MK
authors.lastname: Chung
authors.forename: C K
authors.initials: CK
authors.lastname: Moon
mesh_terms: D000818:Animals; D016718:Arachidonic Acid / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D002118:Calcium / Q000378:metabolism*; D000242:Cyclic AMP / Q000096:biosynthesis*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D009285:Naphthoquinones / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D015230:Prostaglandin D2 / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017482:Receptors, Thromboxane / Q000037:antagonists & inhibitors; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
chemical_list: D004791:Enzyme Inhibitors; C107675:NQ Y15; D009285:Naphthoquinones; D010975:Platelet Aggregation Inhibitors; D017482:Receptors, Thromboxane; D016718:Arachidonic Acid; D000242:Cyclic AMP; D013930:Thromboxane-A Synthase; D015230:Prostaglandin D2; D002118:Calcium